Reply: Higher, but Not Too High, Dose Is Only One Determinant of Corticosteroid Treatment Success in Severe COVID-19.
作者信息
Pitre Tyler, Zeraatkar Dena
机构信息
Department of Respirology University of Toronto Ontario, Canada.
McMaster University Hamilton, Ontario, Canada.
出版信息
Ann Am Thorac Soc. 2023 Sep;20(9):1372. doi: 10.1513/AnnalsATS.202305-436LE.
Abstract
摘要
相似文献
1
Reply: Higher, but Not Too High, Dose Is Only One Determinant of Corticosteroid Treatment Success in Severe COVID-19.
Ann Am Thorac Soc. 2023 Sep;20(9):1372. doi: 10.1513/AnnalsATS.202305-436LE.
2
Higher, but Not Too High, Dose Is Only One Determinant of Corticosteroid Treatment Success in Severe COVID-19.
Ann Am Thorac Soc. 2023 Sep;20(9):1371. doi: 10.1513/AnnalsATS.202304-329LE.
3
High-dose corticosteroid therapy in COVID-19: the RECOVERY trial - Authors' reply.
Lancet. 2024 Apr 6;403(10434):1339-1340. doi: 10.1016/S0140-6736(23)02879-9.
4
The ten reasons why corticosteroid therapy reduces mortality in severe COVID-19. Author's reply.
Intensive Care Med. 2021 Mar;47(3):357-358. doi: 10.1007/s00134-020-06335-5. Epub 2021 Jan 28.
5
Efficacy of corticosteroid treatment for hospitalized patients with severe COVID-19: a multicentre study.
Clin Microbiol Infect. 2021 Jan;27(1):105-111. doi: 10.1016/j.cmi.2020.09.014. Epub 2020 Sep 22.
6
Comparison of pulse-dose and high-dose corticosteroids with no corticosteroid treatment for COVID-19 pneumonia in the intensive care unit.
J Med Virol. 2022 Jan;94(1):349-356. doi: 10.1002/jmv.27351. Epub 2021 Sep 28.
7
Short-term Outcomes of Corticosteroid Monotherapy in COVID-19-Associated Multisystem Inflammatory Syndrome in Children-Handle With Caution-Reply.
JAMA Pediatr. 2022 Sep 1;176(9):946-947. doi: 10.1001/jamapediatrics.2022.2322.
8
Are intravenous corticosteroid pulses superior to low dose corticosteroids in patients with severe COVID-19?
Eur Respir J. 2022 Oct 20;60(4). doi: 10.1183/13993003.01220-2022. Print 2022 Oct.
9
Effects of Corticosteroid Treatment for Non-Severe COVID-19 Pneumonia: A Propensity Score-Based Analysis.
Shock. 2020 Nov;54(5):638-643. doi: 10.1097/SHK.0000000000001574.
10
The proportion and effect of corticosteroid therapy in patients with COVID-19 infection: A systematic review and meta-analysis.
PLoS One. 2021 Apr 21;16(4):e0249481. doi: 10.1371/journal.pone.0249481. eCollection 2021.
本文引用的文献
1
Corticosteroids in Community-Acquired Bacterial Pneumonia: a Systematic Review, Pairwise and Dose-Response Meta-Analysis.
J Gen Intern Med. 2023 Aug;38(11):2593-2606. doi: 10.1007/s11606-023-08203-6. Epub 2023 Apr 19.
2
Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial.
Lancet. 2023 May 6;401(10387):1499-1507. doi: 10.1016/S0140-6736(23)00510-X. Epub 2023 Apr 13.
3
Higher- versus Lower-Dose Corticosteroids for Severe to Critical COVID-19: A Systematic Review and Dose-Response Meta-analysis.
Ann Am Thorac Soc. 2023 Apr;20(4):596-604. doi: 10.1513/AnnalsATS.202208-720OC.
Zotero 插件